ESSA Pharma Statistics
Total Valuation
ESSA Pharma has a market cap or net worth of $271.18 million. The enterprise value is $134.49 million.
Market Cap | 271.18M |
Enterprise Value | 134.49M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, before market open.
Earnings Date | May 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
ESSA Pharma has 44.24 million shares outstanding.
Shares Outstanding | 44.24M |
Owned by Insiders (%) | 2.27% |
Owned by Institutions (%) | 78.72% |
Float | 24.60M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | n/a |
Forward PS | n/a |
PB Ratio | 1.97 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 40.75, with a Debt / Equity ratio of 0.00.
Current Ratio | 40.75 |
Quick Ratio | 40.37 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -5,618.16 |
Financial Efficiency
Return on equity (ROE) is -17.40% and return on invested capital (ROIC) is -22.59%.
Return on Equity (ROE) | -17.40% |
Return on Assets (ROA) | -17.00% |
Return on Capital (ROIC) | -22.59% |
Revenue Per Employee | n/a |
Profits Per Employee | -$516,096 |
Employee Count | 50 |
Asset Turnover | n/a |
Inventory Turnover | n/a |
Taxes
In the past 12 months, ESSA Pharma has paid $1,600 in taxes.
Income Tax | 1,600 |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +130.63% in the last 52 weeks. The beta is 1.69, so ESSA Pharma's price volatility has been higher than the market average.
Beta (1Y) | 1.69 |
52-Week Price Change | +130.63% |
50-Day Moving Average | 8.43 |
200-Day Moving Average | 5.72 |
Relative Strength Index (RSI) | 26.56 |
Average Volume (30 Days) | 128,719 |
Short Selling Information
Short Interest | 802,843 |
Short Previous Month | 928,624 |
Short % of Shares Out | 3.02% |
Short % of Float | n/a |
Short Ratio (days to cover) | 11.26 |
Income Statement
Revenue | n/a |
Gross Profit | n/a |
Operating Income | -31.87M |
Pretax Income | -25.80M |
Net Income | -25.80M |
EBITDA | -25.69M |
EBIT | -25.80M |
Earnings Per Share (EPS) | -$0.59 |
Balance Sheet
The company has $142.38 million in cash and $374,835 in debt, giving a net cash position of $142.00 million or $3.21 per share.
Cash & Cash Equivalents | 142.38M |
Total Debt | 374,835 |
Net Cash | 142.00M |
Net Cash Per Share | $3.21 |
Equity / Book Value | 140.68M |
Book Value Per Share | 3.18 |
Working Capital | 140.34M |
Cash Flow
Operating Cash Flow | -21.57M |
Capital Expenditures | n/a |
Free Cash Flow | -21.57M |
FCF Per Share | -$0.49 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
ESSA Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -0.13% |
Shareholder Yield | -0.13% |
Earnings Yield | -9.33% |
FCF Yield | -7.80% |
Analyst Forecast
The average price target for ESSA Pharma is $17.00, which is 178.69% higher than the current price. The consensus rating is "Buy".
Price Target | $17.00 |
Price Target Difference | 178.69% |
Analyst Consensus | Buy |
Analyst Count | 1 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 25, 2018. It was a reverse split with a ratio of 1:20.
Last Split Date | Apr 25, 2018 |
Split Type | Reverse |
Split Ratio | 1:20 |
Scores
Altman Z-Score | n/a |
Piotroski F-Score | 1 |